ÂÜÀòÂÒÂ×

Larry Hamann is the co-founder, president, and CEO of Interdict Bio, a position held since 2022. They previously served in prominent roles such as Executive Director of Global Discovery Chemistry at Novartis from 2008 to 2016, Vice President of Small Molecule Drug Discovery at Celgene from 2016 to 2020, and Global Head of Drug Discovery Sciences at Takeda from 2020 to 2021. Earlier in their career, they were the Director of Discovery Chemistry at Bristol-Myers Squibb from 1999 to 2008 and Associate Director of Medicinal Chemistry at Ligand Pharmaceuticals from 1992 to 1999. Larry earned a Ph.D. in Organic Chemistry from the University of Michigan and a B.S. in Chemistry from the University of Detroit.